Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Badar T, et al. Among authors: saliba an. Leukemia. 2023 Apr;37(4):799-806. doi: 10.1038/s41375-023-01847-7. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807649
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia.
Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, Atallah E. Badar T, et al. Among authors: saliba an. Cancer. 2023 Mar 15;129(6):934-945. doi: 10.1002/cncr.34604. Epub 2022 Dec 21. Cancer. 2023. PMID: 36545710 Free article.
Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Gangat N, et al. Haematologica. 2024 Jan 1;109(1):187-292. doi: 10.3324/haematol.2023.283732. Haematologica. 2024. PMID: 37534525 Free PMC article. No abstract available.
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Steinauer N, et al. Among authors: saliba an. Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.284962. Online ahead of print. Haematologica. 2024. PMID: 38546692 Free article.
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E. Murthy GSG, et al. Among authors: saliba an. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285014. Online ahead of print. Haematologica. 2024. PMID: 38572562 Free article.
Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN, Gangat N. Saliba AN, et al. Best Pract Res Clin Haematol. 2022 Jun;35(2):101379. doi: 10.1016/j.beha.2022.101379. Epub 2022 Aug 30. Best Pract Res Clin Haematol. 2022. PMID: 36333070 Review.
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Jia J, Ji W, Saliba AN, Csizmar CM, Ye K, Hu L, Peterson KL, Schneider PA, Meng XW, Venkatachalam A, Patnaik MM, Webster JA, Smith BD, Ghiaur G, Wu X, Zhong J, Pandey A, Flatten KS, Deng Q, Wang H, Kaufmann SH, Dai H. Jia J, et al. Among authors: saliba an. Cell Death Differ. 2024 Apr;31(4):405-416. doi: 10.1038/s41418-024-01283-9. Epub 2024 Mar 27. Cell Death Differ. 2024. PMID: 38538744
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Badar T, et al. Among authors: saliba an. Blood Cancer J. 2024 Feb 20;14(1):32. doi: 10.1038/s41408-024-01000-2. Blood Cancer J. 2024. PMID: 38378617 Free PMC article.
55 results